Inventors:
Robert Gatenby - Tucson AZ, US
International Classification:
A61K051/00, A61K048/00
Abstract:
The present invention provides methods of treating proliferative disorders in vivo by the direct administration of tritium to target cell nuclei. Tritium is administered to target cell nuclei by a tritiated nuclear targeting agent, which is directed to the target cell nucleus where it associates with the cell's DNA. The close association of the tritiated nuclear targeting agent with the target cell DNA allows the low-energy beta particle emitted by the tritium to damage to the target cell DNA and kill the cell. Tritiated nuclear targeting agents can also be delivered to the target cells by structures such as liposomes, micelles and microcapsules.